Direct disease-inducing effects of menthol through the eyes of tobacco companies

M Victoria Salgado,1 Stanton A Glantz2

ABSTRACT
Objective Menthol is an important additive in most tobacco products and is an identifying characteristic of many brands. We assessed tobacco companies’ research on direct disease-inducing effects of menthol and menthol cigarettes.

Methods A search was conducted among documents included in the Legacy Tobacco Documents Library. Relevant documents addressed subject areas such as pharmacology, short-term and long-term effects and biomarkers of smoking exposure.

Results The documents contain little internal industry research on the disease-inducing effects of menthol. Most information in the tobacco industry documents are reviews of the published biomedical literature, from which the companies concluded that menthol did not have any direct disease-inducing effects. Evidence that contradicted this conclusion was downplayed. Except for one study, there was no evidence of the companies following up on positive findings in the literature with their own studies. In one case, results were presented at a public scientific meeting concluding that ‘there were no effects from addition of menthol to test or reference cigarettes’, when a company’s internal pathology analysis contradicted this statement.

Conclusion The available industry documents suggest that tobacco companies conducted little research on the potential disease-inducing effects of menthol and did not pursue studies that suggested adverse effects.

INTRODUCTION
Though menthol has been used in foods and confections for many years, this does not necessarily mean that its addition to cigarettes (which are burned and then inhaled) is innocuous. Although a 2010 published paper from the Lorillard Tobacco Company states that ‘menthol employed as a cigarette tobacco flavoured ingredient does not meaningfully affect the inherent toxicity of cigarette smoke or the human risks that attend smoking’,1 this conclusion is not supported by all the scientific literature. In a 2010 commentary, Hammons noted that although a limited number of epidemiological studies that examined the relation between menthol cigarette smoking and disease risk found no association with increased deaths from cancer, coronary heart disease or other cardiovascular diseases, their limitations (including the difficulty in classifying subjects as exclusively menthol or non-menthol smokers for a long enough time or large enough sample size to detect an increment in risk above the large risk caused by smoking in general) caution against treating these results as conclusive.2 The presence of menthol and alcohol increases the flux of tobacco carcinogens across porcine oesophagus3 and menthol enhances the penetration of nicotine through porcine buccal mucosa4 in vitro systems. Menthol might also inhibit the detoxification of the potent carcinogen NNAL.5 In addition, menthol’s interaction with biomarkers of smoking exposure such as cotinine and carbon monoxide remains unclear: published studies have shown contradictory results,5–7 with one of these studies8 published by the Altria Client Services Inc, part of Altria/Philip Morris.

Although menthol is a Food and Drug Administration (FDA) approved food additive, the FDA is now evaluating menthol as a cigarette additive. This paper summarises studies that were either conducted or supported by tobacco companies concerning the direct disease-inducing effects of menthol.

METHODS
A search was conducted among the tobacco industry documents in the University of California, San Francisco Legacy Tobacco Documents Library (LTDL), which contains more than 11 million documents created by major tobacco companies related to their advertising, manufacturing, marketing, sales and scientific research activities.9 As described in detail in this supplement by Anderson’s paper on research methodology,10 Based on the questions posed by the FDA, initial keyword searches combined terms related to menthol, adverse effects, carcinogen, pharmacokinetics, cotinine, carboxyhaemoglobin. This initial set of keywords resulted in the development of further search terms and combinations of keywords (eg, biomarker, permeation, conjugation). Relevant documents addressed the pharmacology of menthol, short-term and long-term effects of menthol, role of menthol on disease risk and menthol’s effects on biomarkers of smoking exposure. A final collection of 209 documents was deemed relevant to this study. Nineteen documents that provided illustrative, detailed or exemplary information supporting these themes are cited in this paper.

RESULTS
Pharmacokinetics of menthol
Internal tobacco company research
In the early 1970s, the British American Tobacco (BAT) Company commissioned a confidential literature survey by the British Industrial Biological Research Association (BIBRA) that established the paucity of definitive data on the pharmacodynamics and pharmacokinetics of menthol following ingestion and inhalation in either experimental animals or humans.12 During that time (1974), the World Health Organization was discussing what
would be an acceptable maximum daily intake for orally ingested menthol. In response, in 1975, BAT worked to develop analytical chemical methods to detect menthol in blood samples, including preliminary studies using data collected from two middle-aged BAT scientists who switched from their regular cigarettes to mentholated cigarettes and also ingested menthol orally. The study found blood levels of menthol below 10 ppb (parts per billion) in all but one experiment that involved only one of the subjects smoking 32 cigarettes in an 8-hour period, where 40 ppb of menthol was measured.

In 1976, the contract research organisation Life Science Research delivered a ‘confidential’ report to the BAT’s Group Research & Development Centre summarising animal experiments to determine absorption and pharmacokinetics of orally administered menthol. Four protocols of oral administration of menthol to rats were conducted, with subsequent collection of blood and urine samples. In one of these experiments, in which 224 rats were used, adipose and liver tissue samples were taken from a subsample of the rats. A fifth experiment was conducted using one male dog to examine for possible species variation in absorption and elimination of menthol. Free and conjugated menthol (glucuronide, which the body produces by reacting menthol with glucuronic acid to facilitate excretion) were measured. Menthol was found to be poorly absorbed after oral administration in both species (less than 2% of the oral dose was recovered in the urine of rats over the first 48 hours), and to be excreted mostly as glucuronide (conjugated menthol) in urine. Liver samples taken 8 weeks after the beginning of a daily oral administration of menthol showed an increase in the activity of hepatic UDP-glucuronyl transferase that seemed to be dose-dependent, suggesting that menthol was metabolised by the liver and that this was the enzyme that conjugates menthol. Menthol was not found in any of the samples of adipose tissue analysed.

A second Life Science Research report delivered in 1976 described five protocols using rats, guinea pigs, mice and hamsters. Of these five experiments, two rats were used in the one with the smaller sample size, while groups of 24 mice, hamsters and guinea pigs were used for the experiment with the biggest sample size. In all cases, radiolabelled menthol was administered by intraperitoneal injection. Maximum average blood levels of radioactivity were observed within 2 hours in all four species. Menthol was excreted mostly as glucuronide in urine, with some excretion through faeces.

A 1978 report from the BAT’s Group Research and Development Centre described two studies performed using human subjects (three in one study and five in the other). Participants were told to smoke mentholated cigarettes during the day. Urine samples were collected in both studies before and after the smoking period and blood sample were taken in one study. When comparing the pre-smoking and post-smoking blood samples, no increase in the levels of free menthol were found after smoking up to 21 cigarettes in an 8-hour period Excretion rate was maximal at the end of the smoking period, with 80–90% of the menthol being eliminated during the smoking period or within 4 hours post-exposure.

Pyrolysis of menthol
Study published in the open literature
In 1968, Nature published a paper (by Schmeltz and Schlottzauer, from the US Department of Agriculture) reporting that the pyrolysis of menthol at 860°C produced benzo[a]pyrene, a mutagen and carcinogen. In 1970, Jenkins et al from Philip Morris’s Research Center published a paper on the pyrolysis of tobacco cigarettes to control menthol delivery and perception. The review did, however, include a summary of the literature to be used in an internal RJ Reynolds training programme entitled ‘Menthol and the design of mentholated cigarettes’. This material aimed to provide a summary of the information researchers needed to design mentholated cigarettes mostly focused on details of how to design mentholated cigarettes to control menthol delivery and perception. The review did, however, include a summary of the literature on health effects, which concluded that no long-term studies (greater than 1 year) of the effects of menthol cigarettes were found in the literature and that, while case reports in humans had appeared, the lack of controls in these cases made the results questionable, that ‘menthol is not carcinogenic, as shown in studies by [the National Cancer Institute]’ and that ‘no detrimental effects of menthol were observed in short term biological studies’.

In 1988, as part of its research to develop Premier cigarette (a new product that delivered nicotine by heating beads covered with nicotine rather than burning tobacco) RJ Reynolds developed 90-day inhalation study (denoted TRD-ATS-017) to ‘compare toxicological responses produced by menthol and non-menthol test [heated tobacco] and reference [burned tobacco] cigarettes … [using] 12 groups each containing up to 55 Sprague-Dawley rats per sex. Three graded concentrations of smoke from both sets [menthol and non-menthol] of test and reference cigarettes will be used, and the comparisons of test and reference will be made on the basis of the amounts of wet total particulate matter (WTPM) presented to the animals.’

Long-term and short-term studies on the effects of menthol
Document developed for external release
In 1963, the Liggett & Myers Tobacco Company prepared a report for the Surgeon General’s Advisory Committee on Smoking and Health reporting on long-term carcinogenicity assays in mice and rabbits. Using 100 female mice, smoke condensates were applied to the back of the animals and the rate of incidence and time of appearance of skin papillomas and carcinomas were recorded (follow-up period: 24 months). The incidence of tumours in mice painted with the condensate from mentholated cigarettes was not significantly different from that observed with condensates from non-mentholated cigarettes.
Endpoints included histopathology, plasma levels of nicotine and cotinine, haematology, organ and body weights and measurements of respiratory physiology. The results of this study were to be kept confidential inside RJ Reynolds; the protocol stated, ‘This study will not be listed as a regulated study and the results are not intended to be submitted to any regulatory agency’.24

In 1990, RJ Reynolds submitted an abstract for the Society of Toxicology annual meeting, reporting the results of study TRD-ATS-017, that stated ‘There were no effects from addition of menthol to test or reference cigarettes’.25 Later that same year, however, the TRD-ATS-017 final histopathological report, prepared for internal RJ Reynolds’ use, concluded that ‘for the reference [conventional] cigarette, the histopathological changes noted in the upper airways of the menthol cigarette groups were more severe than those noted in the non-menthol cigarette groups’.26 Four years later, in May 1994, RJ Reynolds dismissed the results in an interoffice memorandum,23 arguing that the comparisons between the reference cigarettes were not valid since the configuration of the two cigarettes was different. The same memo stated that ‘no comparisons across reference groups were required in the study protocol and are also not germane to the purpose of this study’.23 But in August 1994, the RJ Reynolds scientific and regulatory affairs team27 questioned the reasons for dismissing the results because:

This argument is made principally on the grounds that the two cigarettes are in fact different with respect to distinct blend and physical characteristics. However, given that the mentholated conventional product utilized as a control in this study contained no reconstituted tobacco sheet and more non-menthol ingredients, one would have predicted that it would have displayed reduced activity relative to the Kentucky 1R4F [non-menthol] reference cigarette. In short, study TRDATS-017 may have understated the potential for menthol to produce adverse effects.27

A PM confidential ‘Risk Assessment for Menthol’ prepared by Philip Morris Product Integrity in 199926 provided a comprehensive review of the regulatory environment around menthol and the state of the open literature. It remarked that most studies using human subjects were case reports and that conclusions were therefore anecdotal. It also concluded that, considering the ubiquitous use of menthol, it was almost certain that the presence of clinical symptoms in those cases (such as a case of psychological disturbance caused by 3 years of nasal medication that contained menthol) were due to instances of extreme exposure.20 The review also contained results from a few unpublished PM internal studies, including results from eye and skin irritation studies. Results of the primary skin irritation test in rabbits using showed no dermal irritation. When instilling microcapsules into the rabbit’s eye, slight conjunctival redness was observed 1 hour after dosing, but later evaluations at 24, 48 and 72 hours post-treatment showed no irritation. The final conclusion was that menthol was non-irritating. Under the same protocol, a second study of microcapsules instillations produced a group average score of two (out of possible 110) at 24 hours and 48 hours after treatment and this response resolved by 72 hours post-treatment, led to the conclusion that menthol was minimally irritating to the rabbit eye.20 The risk assessment did note that there was some evidence that menthol had adverse health effects, but dismissed these studies on technical grounds. For example:

Epidemiology presents conflicting data with respect to biological effects from mentholated cigarette smoke in humans. African American men have been reported to have a 60% higher lung cancer incidence than the US white male population. Although the number of cigarettes smoked per day is significantly lower among African Americans, they smoke cigarettes with higher tar content. Fifty-five percent of African Americans smoke mentholated brands of cigarettes. Some studies have reported increases in lung cancer incidence in long-term mentholated cigarette smoking individuals from different races, while other studies report menthol smoking is not a strong risk factor for lung cancer. Although many hypotheses have been advanced with respect to the possible mechanisms associated with the reported lung cancer ‘increases’, these hypotheses remain unproven. Confounding factors such as socioeconomic status, access to health care, quality and usage of care, smoking behavior, physiological changes from menthol affecting smoking mechanics, and racial differences in levels and activity of P450 enzymes have generally not been evaluated in this context.28

The conclusion of the report was that ‘There are no anticipated risks associated with the use of menthol in cigarettes at the current application levels’.26

In 2001, Philip Morris prepared an extensive review of regulatory issues related to menthol, together with an extensive summary of the available scientific literature, including some internal studies on smoke chemistry. (The intended audience for this report is not clear.) This review reported the evidence of adverse effects on pulmonary function in workers exposed to menthol, epidemiological evidence linking smoking menthol cigarettes with lung cancer in men and oesophageal cancer in women, and that adding menthol increased the amount to total particulate matter in the smoke, but downplayed these results, concluding that ‘menthol has a low order of acute toxicity and has been demonstrated to be non-carcinogenic and non-teratogenic’.29

Study published in the open literature
In 1999, RJ Reynolds published the results from a study30 31 that assessed psychophysiological (EEG and heart rate) and subjective (such as mental alertness and anxiety/nervousness) effects of smoking menthol versus non-menthol cigarettes smokers using denicotinised cigarettes (to study the effects of menthol independently of the effects of nicotine). Twenty-two volunteers (12 regular menthol smokers, 10 regular non-menthol smokers) were recruited. Both type of smokers smoked two commercial denicotinised cigarettes (which still contain low levels of nicotine); menthol and non-menthol. Menthol smokers showed a greater increase in heart rate following smoking either cigarette (around 5 bpm) than did non-menthol smokers (around 2 bpm), which could indicate that menthol smokers were more sensitive to the low levels of nicotine in the denicotinised cigarettes, implying they could be more sensitive to the effects of nicotine itself. Menthol smokers had a slower EEG alpha rhythm (9.35 Hz) than non-menthol smokers (10.08 Hz) with the eyes closed, leading to the conclusion that regular menthol smokers seemed to be less aroused by menthol than regular non-menthol smokers.30 31 The conclusion in the abstract of the draft manuscript located in the industry documents was ‘We also report evidence that menthol smokers may be chronically less aroused and more sensitive to the effects of nicotine than non-menthol smokers’.32

In the published paper, an additional conclusion was added to the abstract: ‘We found little evidence that menthol in cigarettes has central pharmacological effects’.30 31

Menthol, nicotine, cotinine and carbon monoxide
Study published in the open literature
In 1997, Lorillard published an article in Food and Chemical Toxicology33 34 reporting the results of a study of two rats

Research paper
inhalng smoke non-menthol (reference) or menthol cigarettes (21 rats per sex for reference and 15 per sex for menthol) for an hour a day, 5 days a week, for 13 weeks. Within each group, three different concentrations of target smoke were used (200 mg/m³, 600 mg/m³ and 1200 mg/m³ TPM), defining three subgroups. A third group of rats (15 per sex) exposed to filtered air was used as control. The objective was ‘to determine any significant alteration of smoke-related biological effects resulting from menthol addition’.

At the 200 mg/m³ smoke concentration, cotinine levels were lower among the menthol group (118.6 (SD ±21.6) ng/ml vs 144.1 (SD ±20.1) ng/ml; p=0.05). Authors interpreted this finding as ‘apparently incidental’.

The final conclusion was that ‘The results of this 13-week inhalation study of mentholated tobacco smoke indicate that the addition of menthol to cigarettes does not significantly alter the pattern, incidence, severity or reversibility of any of the effects attributable to smoke exposure in rats’.

**Menthol and cell permeability**

**Study published in the open literature**

A study published in 1983 partially funded by the Swedish Tobacco Company analysed the toxicity of menthol using four different in vitro systems: trachea from chicken embryos, ascorbic acid, breast cancer cell lines and rat liver mitochondria. In the mitochondrial model, menthol was found to cause an increase in the state four respiratory rate and osmotic swelling, indicating a leakage of the mitochondrial membrane. The authors suggested that one effect of menthol could be a deterioration of biological membranes.

**DISCUSSION**

This paper assessed tobacco industry research on potential direct disease-inducing effects of menthol and mentholated cigarettes. In the studies presented here, menthol is described as an additive that does not accumulate in people smoking up to 21 cigarettes, that is metabolised in the liver and that is mostly excreted in urine as glucuronide.

Menthol’s effect on levels of biomarkers of smoke exposure is less well examined; however, one in-house study concluded menthol does not modify them. Menthol was also suggested to degenerate biological membranes and to produce more severe histopathological changes in the upper airways when compared to non-menthol cigarettes. Menthol itself is presented as a non-carcinogenic substance. There is a lack of information on other long-term effects.

Results from the 1978 BAT’s Group Research and Development Center study on menthol’s pharmacokinetics on humans were not reproduced in an article published in 1999. While the BAT study found that 80–90% of the menthol was eliminated during the smoking period or within 4 hours post-exposure, Gelal et al reported that the recovery of administered menthol as the glucuronide averaged only 45.6% and 56.6% in 24-hour urine samples. In the BAT study menthol was absorbed through smoking mentholated cigarettes, while in Gelal’s study, menthol was orally administered.

Regarding RJ Reynolds’ large TRD-ATS-017 study, the company decided to present results at a public scientific meeting indicating that ‘There were no effects from addition of menthol to test or reference cigarettes’ when the company’s internal pathology analysis contradicted this statement. There was an attempt to discard this conclusion internally as well, a position contested inside the company. In any event, the histopathological results suggesting an adverse effect of menthol do not appear to have been published. We did not find evidence that RJ Reynolds did additional research designed to resolve the internal controversy about whether or not menthol had adverse histopathological effects.

Most of the information on menthol’s direct disease-inducing effects found among the tobacco industry documents comes from summaries that the companies prepared of the open biomedical literature, not from studies carried out by the companies themselves. The presence of several scientific literature reviews developed for internal purposes (such as training) seem to indicate that the industry in most cases considered this information to be sufficient to conclude that menthol did not have any direct disease-inducing effects. Evidence that contradicted this conclusion was downplayed. The companies did not seem interested in following up on the positive findings in the literature with their own studies, except for one study designed to counter the conclusion that menthol was pyrolysed into the carcinogen benzo(a)pyrene.

Overall, menthol’s main health effects seem to be indirect. For example, a 2010 paper that examined differences between self-reported health characteristics for menthol and non-menthol smokers using data from the 2005 National Health Interview Survey found that a larger proportion of current menthol smokers reported having asthma and that former menthol smokers reported a higher proportion of emergency room visits due to asthma. The authors suggested that ‘perhaps the ‘cooling’ and ‘soothing’ effects of menthol allow smokers to engage longer in smoking behaviours that over an extended period of time may produce asthma-related symptoms that account emergency room visits’. This study also found that the mean number of cigarettes smoked per day was borderline significantly lower for menthol smokers when compared to non-menthol smokers controlling for sex, age and race in a multivariate analysis (OR: 0.99, 95% CI 0.98 to 1.00). In contrast, another analysis of the same dataset that stratified on race/ethnicity (African American, Hispanic and white) and gender, controlling for age, income and education, did not find a significant difference in the number of cigarettes smoked per day between menthol and non-menthol smokers within each ethnic group.

Evidence from internal tobacco documents research shows that menthol interacts directly with nicotine, affecting nicotine delivery and that addition of menthol to cigarettes has been used to reduce smokers’ concerns about the health effects of cigarettes and to attract and retain new, younger smokers. Menthol also reduces the negative sensory characteristics associated with smoking and may encourage experimenters who find non-mentholated cigarettes too harsh to progress to regular smoking rather than quitting, and may

---

**What is already known about this topic**

Menthol is an important additive in most tobacco products and is an identifying characteristic of many brands, yet there has been little research into its direct disease-inducing effects.

**What this study adds**

Despite its importance and the widespread use of menthol as an additive in tobacco products, the available industry documents suggest that tobacco companies conducted little research on the potential disease-inducing effects of menthol and did not pursue studies that suggested adverse effects.
inhibit the desire to quit among established menthol smokers who have become accustomed to the taste and sensation of menthol cigarettes. Nevertheless, in the documents located, the tobacco industry has avoided integrating this information when discussing the disease-inducing effects of menthol.

Acknowledgements The authors thank Rachel Taketa for her invaluable work in document searching and Vera Harrell for administrative support.

Funding This research was supported by the Department of Health and Human Services Contract HHSN261201000035I and NCI grant CA-87472. Staff from the Food and Drug Administration offered comments on the original white paper authored by MVS.

Competing interests None.

Contributors MVS prepared the original FDA white paper that forms the basis for this paper. SAG worked with her to build on that work to prepare this manuscript.

Provenance and peer review Not commissioned; externally peer reviewed. This peer reviewed paper is based on a longer, more detailed (but not peer reviewed) white paper prepared for the US Food and Drug Administration. The full white paper is available at http://www.escholarship.org/uc/item/95m417v2 and http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoProductsScientificAdvisoryCommittee/ucm226004.htm.

REFERENCES


